107 Drugs Added to China's Basic Insurance List

chinadaily.com.cn
2026-11-16

China has added 107 drugs to its updated medical insurance drug list, including a record 51 first-in-class innovative medicines, while prioritizing treatments for cancer, rare diseases and other conditions with significant unmet clinical needs.

The updated list, released on November 14, 2026, will take effect on January 1, 2027. The administration has adjusted the list annually for nine consecutive years.

With 34 drugs removed due to limited clinical value, better alternatives or supply constraints, the updated insurance catalog now includes 3,331 drugs, comprising 1,935 Western medicines and 1,396 traditional Chinese medicine products.

Among the newly added drugs, 31 are for tumors, 18 target rare diseases and 24 address chronic conditions, while the remainder cover areas such as infectious diseases and mental health.

The list marks the inclusion of the first CAR-T cell therapy, a novel and often expensive treatment for cancer.

The administration unveiled the updated commercial insurance innovative drug list, the second iteration since its inception in 2025.

The list included 12 new drugs, bringing the total to 28. It is focused on highly innovative medicines that are too costly for basic insurance but are recommended for commercial health coverage.

Newly added treatments include frontier therapies such as cell and gene therapies, as well as more advanced therapies for rare diseases and cancer.

Currently, annual drug sales driven by the medical insurance list have surpassed 170 billion yuan, four times higher than five years ago.

Attachment